{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:53:54Z","timestamp":1772834034512,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.pnpbp.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:02:37Z","timestamp":1504569757000},"page":"367-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-6752","authenticated-orcid":false,"given":"Adjia","family":"Hamadjida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2017.09.001_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0028-3908(88)90149-9","article-title":"Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers","volume":"27","author":"de Boer","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0030","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0035","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0045","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease","volume":"353","author":"French Clozapine Parkinson Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","article-title":"Parkinson disease psychosis: update","volume":"27","author":"Friedman","year":"2013","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02274901","article-title":"Comments and reply on Ikeguchi and Kuroda: mianserin treatment of patients with psychosis induced by antiparkinsonian drugs","volume":"246","author":"Friedman","year":"1996","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","article-title":"The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset","volume":"234","author":"Hamadjida","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson's disease: non-l-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0075","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0080","doi-asserted-by":"crossref","first-page":"e45587","DOI":"10.1371\/journal.pone.0045587","article-title":"The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset","volume":"7","author":"Huot","year":"2012","journal-title":"PLoS One"},{"issue":"194","key":"10.1016\/j.pnpbp.2017.09.001_bb0085","first-page":"e5","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","article-title":"UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset","volume":"82","author":"Huot","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF02190411","article-title":"Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs","volume":"244","author":"Ikeguchi","year":"1995","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.2042-7158.1997.tb06814.x","article-title":"A comparison of the physicochemical and biological properties of mirtazapine and mianserin","volume":"49","author":"Kelder","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0028-3908(94)90081-7","article-title":"Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells","volume":"33","author":"Kooyman","year":"1994","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0378-4347(88)80088-4","article-title":"High-performance liquid chromatographic determination of mianserin in plasma and brain and its application to pharmacokinetic studies in the rat","volume":"434","author":"Kurata","year":"1988","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0115","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","article-title":"Parkinson's disease. First of two parts","volume":"339","author":"Lang","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40780-016-0046-7","article-title":"The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study","volume":"2","author":"Nawata","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"issue":"1","key":"10.1016\/j.pnpbp.2017.09.001_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF03189313","article-title":"Pharmacokinetics of mianserin.hcl (Org GB 94) in the isolated perfused rat liver and in the anasthetized rat","author":"de Nijs","year":"1977","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-0447.1983.tb00359.x","article-title":"Pharmacological aspects of mianserin","volume":"302","author":"Pinder","year":"1983","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2017.09.001_bb0140","doi-asserted-by":"crossref","first-page":"313S","DOI":"10.1111\/j.1365-2125.1983.tb05880.x","article-title":"The pharmacokinetics of mianserin","volume":"15","author":"Shami","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e3181c47168","article-title":"Current use of clozapine in Parkinson disease and related disorders","volume":"33","author":"Thomas","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0150","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pnpbp.2017.09.001_bb0155","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617306061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617306061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T23:50:03Z","timestamp":1535413803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584617306061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":31,"alternative-id":["S0278584617306061"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.09.001","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}